newsfilter
← Latest News
GlobeNewswire·

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly